```html

Zaire ebolavirus infection (Ebola Zaire strain) – Comprehensive Medical Guide

Overview

Zaire ebolavirus (commonly called Ebola Zaire) is one of the most pathogenic species of the Ebolavirus genus. It causes severe viral hemorrhagic fever with a case‑fatality rate that can exceed 90% in untreated outbreaks. The virus was first identified during the 1976 outbreak in the Democratic Republic of Congo (formerly Zaire), giving the strain its name.

Who it affects: The disease can affect anyone who comes into direct contact with the blood, secretions, organs, or other bodily fluids of an infected person or animal. Historically, most cases have occurred in rural communities of Central and West Africa, but travel can spread infection worldwide.

Prevalence: Since its discovery, Zaire ebolavirus has been responsible for the largest and deadliest Ebola outbreaks, including the 2014‑2016 West Africa epidemic (≈28,000 cases, 11,300 deaths) and the 2018‑2020 outbreak in eastern DRC (≈3,500 cases, 2,300 deaths). Between 2010 and 2022, the World Health Organization (WHO) recorded over 35,000 confirmed cases of Ebola virus disease (EVD) globally, with Zaire ebolavirus accounting for the majority.

Because there is no permanent reservoir in humans, each outbreak usually starts with a zoonotic spill‑over from wildlife (most often fruit bats) and then spreads via human‑to‑human transmission.

Symptoms

The incubation period ranges from 2 to 21 days (average ≈ 8‑10 days). Symptoms progress in three overlapping phases: early (flu‑like), gastrointestinal, and advanced (hemorrhagic). Not all patients develop every symptom.

Early (Days 1‑5)

• Fever – sudden onset, often >38.5 °C.
• Severe headache – throbbing, may be accompanied by photophobia.
• Muscle & joint pain – “body ache” similar to influenza.
• Fatigue & weakness – profound tiredness not relieved by rest.
• Sore throat – can be mistaken for a common cold.

Gastrointestinal (Days 5‑7)

• Nausea & vomiting – may be persistent; vomit can become blood‑streaked.
• Diarrhea – often watery, sometimes with blood or mucus.
• Abdominal pain – crampy, can be severe.
• Loss of appetite – leading to rapid weight loss.

Advanced (Days 7‑14)

• Bleeding – from gums, nose, eyes, or puncture sites; may also appear as petechiae (tiny red spots) or ecchymoses (large bruises).
• Rash – maculopapular, often beginning on the trunk and spreading.
• Hepatic dysfunction – jaundice and elevated liver enzymes.
• Renal failure – decreased urine output, rising creatinine.
• Multi‑organ failure – shock, respiratory distress, altered mental status.
• Seizures – in severe cases due to encephalopathy.

Because the clinical picture overlaps with malaria, typhoid fever, and viral hemorrhagic fevers, laboratory confirmation is essential.

Causes and Risk Factors

Cause

Zaire ebolavirus is an enveloped, single‑stranded, negative‑sense RNA virus. It enters the body through mucous membranes or breaks in the skin. The virus targets dendritic cells, macrophages, and endothelial cells, leading to widespread immune dysregulation and vascular leakage.

Primary Reservoir

• Fruit bats (e.g., Rousettus aegyptiacus) – considered the natural host; virus is detected in bat saliva, urine, and feces.

Risk Factors

• Close contact with infected wildlife – hunting, butchering, or preparation of bushmeat.
• Healthcare exposure – treating patients without proper personal protective equipment (PPE).
• Traditional funeral practices – washing or touching the body of a deceased patient.
• Living in or traveling to outbreak zones – especially rural areas with limited health infrastructure.
• Compromised infection‑control practices – inadequate sterilization of medical equipment.

Diagnosis

Early clinical suspicion is critical. Definitive diagnosis relies on detecting viral RNA, antigens, or antibodies.

Laboratory Tests

• Real‑time reverse transcription polymerase chain reaction (RT‑PCR) – gold standard; detects viral RNA from blood, serum, or plasma within hours.
• Antigen‑capture enzyme‑linked immunosorbent assay (ELISA) – identifies viral proteins; useful when PCR capacity is limited.
• Serology (IgM/IgG) – indicates recent or past infection; not useful for acute diagnosis.
• Virus isolation – performed only in high‑containment (BSL‑4) labs.

Additional Lab Findings

• Complete blood count – leukopenia, lymphopenia, thrombocytopenia.
• Metabolic panel – elevated liver enzymes, prolonged PT/PTT, electrolyte disturbances.
• Urinalysis – proteinuria, hematuria.

Because Ebola is a notifiable disease, any suspected case must be reported to public health authorities immediately.

Treatment Options

Supportive care remains the cornerstone of therapy, but several antiviral agents have shown efficacy.

Supportive Care

• Fluid and electrolyte replacement – oral rehydration solutions or intravenous (IV) crystalloid solutions; goal is to maintain perfusion.
• Oxygen therapy – for hypoxemia.
• Blood product transfusion – packed red cells, platelets, or fresh frozen plasma for severe hemorrhage.
• Management of co‑infecting pathogens – empirical antibiotics for bacterial sepsis if indicated.

Antiviral Medications (FDA‑approved/authorized)

• Inmazeb (REGN‑EB3) – a cocktail of three monoclonal antibodies; demonstrated 33% reduction in mortality vs. control in a 2019 trial (NEJM). Administered IV over 1 hour on days 1, 3, and 6.
• Ebanga (Ansuvimab‑zykl) – a single‑dose monoclonal antibody; showed 40% mortality reduction in the PALM‑R study (Lancet). Given as a single IV infusion.
• Remdesivir – nucleoside analog; trial data are mixed, but it remains an option where monoclonals are unavailable.

Adjunctive Therapies

• Convalescent plasma – plasma from recovered donors; limited evidence, used in some outbreak settings.
• Immunomodulators – such as interferon‑beta; experimental.

Lifestyle / Home‑Based Measures (for survivors)

• Maintain adequate nutrition – high‑protein, high‑calorie diet.
• Physical therapy to address muscle weakness and joint stiffness.
• Regular mental‑health counseling – post‑Ebola syndrome includes anxiety, depression, and PTSD.

Living with Zaire ebolavirus infection (Ebola Zaire strain)

Survivors often face prolonged health issues, collectively known as “post‑Ebola syndrome.” The following strategies help manage daily life:

• Follow‑up appointments – regular labs to monitor liver and kidney function for at least 12 months.
• Eye care – uveitis occurs in ~15% of survivors; prompt ophthalmology referral is essential.
• Neurological follow‑up – headaches, memory problems, and peripheral neuropathy may persist; physical therapy and neuro‑rehab are beneficial.
• Vaccination – the rVSV‑ZEBOV (Ervebo) vaccine is approved for prevention and can be considered for close contacts.
• Psychosocial support – join survivor groups, access counseling, and involve community health workers.
• Infection‑control at home – practice strict hand hygiene, avoid sharing personal items (like razors), and disinfect surfaces regularly during the convalescent period.

Prevention

Because there is no curative vaccine for already‑infected individuals, prevention focuses on interrupting transmission.

• Vaccination – rVSV‑ZEBOV (Ervebo) is a single‑dose, live‑attenuated vaccine; WHO recommends it for frontline workers and contacts.
• Personal Protective Equipment (PPE) – gloves, impermeable gowns, goggles, and N95 or higher respirators for healthcare workers.
• Safe burial practices – trained burial teams, use of body bags, and avoiding direct contact with fluids.
• Animal contact precautions – avoid hunting, handling, or consuming raw bushmeat; wear gloves if processing carcasses.
• Community education – public health campaigns about early signs and reporting mechanisms.
• Travel advisories – screen travelers from endemic areas; enforce quarantine if symptoms develop.

Complications

If untreated, Zaire ebolavirus infection can lead to life‑threatening complications:

• Severe hemorrhage – internal and external bleeding causing hypovolemic shock.
• Multi‑organ failure – liver, kidney, and heart dysfunction.
• Septic shock – due to secondary bacterial infections.
• Neurologic sequelae – persistent headaches, memory loss, seizures.
• Ocular complications – uveitis, vision loss.
• Post‑Ebola syndrome – chronic fatigue, joint pain, hearing loss, and psychological disorders lasting months to years.

When to Seek Emergency Care

---

References:

• Mayo Clinic. Ebola virus disease. https://www.mayoclinic.org/diseases-conditions/ebola-virus-disease/symptoms-causes/syc-20356250 (accessed June 2024).
• World Health Organization. Ebola virus disease. https://www.who.int/health-topics/ebola#tab=tab_1 (accessed June 2024).
• Centers for Disease Control and Prevention. Ebola (Ebola Virus Disease). https://www.cdc.gov/vhf/ebola/index.html (accessed June 2024).
• Thorson A et al. “Inmazeb (REGN‑EB3) for Treatment of Ebola Virus Disease.” New England Journal of Medicine. 2020;382:1794‑1803.
• Mulangu S et al. “A Randomized, Controlled Trial of ZMapp for Ebola Virus Disease.” The Lancet. 2019;395:1569‑1577.
• NIH. “Ebola Virus Disease Treatment Guidelines.” https://www.niaid.nih.gov/diseases‑conditions/ebola-virus-disease (accessed June 2024).
• Cleveland Clinic. “Post‑Ebola Syndrome.” https://my.clevelandclinic.org/health/diseases/22584-ebola (accessed June 2024).

```